Descripción del proyecto
Un dispositivo para tratar complicaciones tras una cirugía cardíaca
Después de una intervención quirúrgica cardíaca, muchos pacientes desarrollan fibrilación auricular posoperatoria (FAPO), un tipo de arritmia que triplica el riesgo de sufrir un accidente cerebrovascular. El proyecto DefiPace-System, financiado con fondos europeos, comercializará un dispositivo que facilita la prevención y el tratamiento de la FAPO en pacientes sometidos a una operación para evitar el uso de medicamentos. El dispositivo ayuda al corazón a restablecer su ritmo normal a través de un proceso conocido como estimulación biauricular, que no requiere anestesia. Es más, este dispositivo es de bolsillo, fácil de utilizar y puede emplearlo el personal clínico en la unidad de hospitalización general de cualquier hospital.
Objetivo
The incidence of cardiac surgeries is increasing world-wide in view of the demographic change. Cardiac surgery carries a
significant amount of risk as on average 60% of patients develop postoperative atrial fibrillation, by far the most frequently
occurring complication after cardiac surgery. Clinical investigations show a significant increase in morbidity, mortality and
duration of treatment and hospital stay. The risk for stroke is increased 3-fold! From all discussions with renowned surgeons
results the clear statement that an avoiding or reduction of medical drugs is in any circumstance a preferable and desirable
ambition. The DefiPace™ system is a proven and awaited method by the physicians treating post-operative patients. Our
new system is unique, as it is the only system in history and today, which allows physicians to prevent and terminate postoperative
atrial fibrillation (POAF) in all patients. It is the only system which combines standard stimulation, bi-atrial pacing
as well as epicardial low-energy cardioversion in one hand-held easy-to-use device even on general ward. Target customers
are all patients undergoing cardiac surgery world-wide (market volume: € 1.5 billion). Advantages: Simplicity • TMA pacing &
cardioversion wires: easy to use, similar to standard pacing wires • DefiPace device: Intuitive handling for clinical staff similar
to standard external pacemakers Prevention and Termination: • Bi-atrial pacing as an effective way to prevent POAF •
Quick Termination of atrial fibrillation with safe, elegant low energy cardioversion • No anesthesia necessary Cost savings
for surgical clinics • Significant cost savings: at least €1,000per day/patient Improved health • Few or no medication
required • All complications from atrial fibrillation can be completely avoided The DefiPace™-System is as a key product for
OSYPKA and will lead to significant increase of sales and employees. We will revolutionize the pacemaker market a second
time in our history
Ámbito científico
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-EIC-SMEInst-2018-2020-3
Régimen de financiación
SME-2b - SME Instrument (grant only and blended finance)Coordinador
79618 Rheinfelden Baden
Alemania
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.